公开(公告)号：US20150196511A1

公开(公告)日：2015-07-16

申请号：US14663235

申请日：2015-03-19

Applicant: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION

Inventor： Mi-La Cho ,  Seon-Yeong Lee ,  Eun-Ji Yang ,  Hye-Jin Son ,  Eun-Kyung Kim ,  Jun-Geol Ryu

IPC: A61K31/155 ,  A61K39/395

CPC classification number: A61K31/155 ,  A61K38/1793 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to a composition comprising metformin as an active ingredient for preventing or treating inflammatory bowel disease. The metformin compound or the metformin-etanercept (product name: Enbrel) composite according to the present invention may have excellent effects of maintaining the thickness of the small intestine and length of the large intestine normal, inhibiting or decreasing the activity of IL-17 and TNF-a, and promoting or increasing the activity of IFNr, and therefore can be effectively used as a pharmaceutical composition for preventing or treating autoimmune diseases including inflammatory bowel disease.

Abstract translation: 本发明涉及包含二甲双胍作为预防或治疗炎症性肠病的活性成分的组合物。 根据本发明的二甲双胍化合物或二甲双胍 - 依那西普（商品名：恩布雷）复合物可以具有保持小肠厚度和大肠长度正常，抑制或降低IL-17活性和 TNF-α，并且促进或增加IFNr的活性，因此可以有效地用作预防或治疗包括炎性肠病的自身免疫性疾病的药物组合物。

公开(公告)号：US20150169940A1

公开(公告)日：2015-06-18

申请号：US14207085

申请日：2014-03-12

Applicant: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION

Inventor： Hang-Bong KANG ,  Myung-Ho JU

IPC: G06K9/00 ,  G06T11/00 ,  G06T7/00

CPC classification number: G06T11/001 ,  G06K9/00275 ,  G06K9/00308 ,  G06K9/621 ,  G06T7/344 ,  G06T2207/30201

Abstract: The method of face model alignment on unseen face includes inputting a face image; warping the face image into a standard shaped face based on a model seen by AAM (Active Appearance Model); normalizing the warped image by removing a texture change of the warped image; extracting a face texture from the normalized image; calculating error areas by comparing the face texture with the seen model; and aligning edges of the face texture with edges of the seen model while reducing the difference of the error areas.

Abstract translation: 不可见面部的面部模型对准方法包括输入面部图像; 基于AAM（活动外观模型）所看到的模型，将脸部图像变形成标准形状的脸部; 通过去除翘曲图像的纹理变化来对变形图像进行归一化; 从标准化图像提取面部纹理; 通过将面部纹理与所看到的模型进行比较来计算误差范围; 并使面部纹理的边缘与所看到的模型的边缘对齐，同时减少误差区域的差异。

公开(公告)号：US20150056226A1

公开(公告)日：2015-02-26

申请号：US14479668

申请日：2014-09-08

Applicant: Catholic University Industry Academic Cooperation Foundation

Inventor： Tai-Gyu KIM

IPC: A61K35/14 ,  C12N15/85 ,  A61K39/00

CPC classification number: A61K35/17 ,  A61K38/1774 ,  A61K38/179 ,  A61K38/2013 ,  A61K39/0011 ,  A61K48/00 ,  A61K2039/5158 ,  C12N5/0636 ,  C12N15/85 ,  C12N2501/2302

Abstract: The present invention is directed to adoptive immunotherapy using a lymphocyte in which an antigen-specific receptor and a bioactive material gene such as an IL-2 gene or a water-soluble TGF-beta receptor gene are transferred. The bioactive material is intensively secreted to, for example, a local site of a tumor, thereby reducing systemic side effects as much as possible, and the survival time of the lymphocyte is increased, thereby further improving the effect of the adoptive immunotherapy.

Abstract translation: 本发明涉及使用淋巴细胞的过继免疫治疗，其中转移抗原特异性受体和生物活性物质基因如IL-2基因或水溶性TGF-β受体基因。 生物活性物质集中分泌到例如肿瘤的局部位点，从而尽可能地减少全身副作用，增加淋巴细胞的存活时间，从而进一步改善过继免疫治疗的效果。

公开(公告)号：US08568978B1

公开(公告)日：2013-10-29

申请号：US13898700

申请日：2013-05-21

Applicant: Catholic University Industry-Academic Cooperation Foundation

Inventor： Hyang-Shuk Rhim ,  Goo-Young Kim ,  Jeong-Mi Moon

IPC: C12Q1/68

CPC classification number: C07K14/52 ,  C07K14/4747 ,  C07K14/7151 ,  C07K2319/42 ,  C12P21/02

Abstract: The present invention relates to a technique for the T7 promoter-driven expression of a foreign protein, preferably, a human protein in E. coli having no T7 RNA polymerase. More particularly, the present invention relates to use of a vector including a T7 promoter and an N-terminal HA tag sequence for overexpression of a foreign protein in E. coli having no T7 RNA polymerase, E. coli that includes the vector and is able to overexpress the foreign protein in the absence of T7 RNA polymerase, a method for expressing or producing the foreign protein using the E. coli, and a method for analyzing functions of the foreign protein. Further, the present invention relates to a simple, rapid method for evaluating the expression and cytotoxicity of a human protein in E. coli by using the vector.

公开(公告)号：US20240165127A1

公开(公告)日：2024-05-23

申请号：US18496519

申请日：2023-10-27

Applicant: DAEGU CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION

Inventor： Sung Won YOUN ,  Phuong Tu HUYNH ,  Huy Duc VU ,  Jung-hwa RYU

IPC: A61K31/555

CPC classification number: A61K31/555 ,  A61K2123/00

Abstract: There is provided a contrast agent for diagnosis of vascular disease containing a gadolinium-based compound as an active ingredient. It has been found that the gadolinium-based compound Gd-DOTA-click-SF of the present disclosure, has a higher molar longitudinal relaxivity (r1) than Dotarem, is stable, and does not affect in vitro cell viability. In addition, it has been found through MRI images that the specific binding of Gd-DOTA-click-SF in an animal model of abdominal aortic aneurysm established using elastase, a serine protease, is remarkable. Also, it has been confirmed that the content of the gadolinium-based compound of the present disclosure that binds to serine protease in the aorta, that is, the content of gadolinium in the aorta, is remarkable. Thus, the Gd-DOTA-click-SF compound according to the present disclosure may be usefully used in MRI and CT imaging diagnosis for vascular disease.

公开(公告)号：US11987496B2

公开(公告)日：2024-05-21

申请号：US17274539

申请日：2019-09-04

Applicant: DAEGU CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION

Inventor： Sang Ryul Lee ,  Kyoung Chol Kim ,  Ja Young Park ,  Ji Hyeong Kim ,  Jeong In Kim ,  Seok Ju Lee ,  Jongyun Jang ,  Seongjeong Lee ,  Mingi Chu ,  Dong Wook Kang

IPC: C01B21/086 ,  C01B21/093

CPC classification number: C01B21/086 ,  C01B21/093

Abstract: A method for producing a bis(fluorosulfonyl)imide lithium salt is disclosed. The method includes the steps of: (a) reacting bis(chlorosulfonyl)imide with NH4F(HF)n (n=0-10) to prepare ammonium bis(fluorosulfonyl)imide; and (b) reacting the ammonium bis(fluorosulfonyl)imide with a lithium base, wherein in at least one of steps (a) and (b), after the reaction, a process of adding an alkoxy trialkyl silane to the reaction solution to remove a fluorine anion is performed.

公开(公告)号：US20230183661A1

公开(公告)日：2023-06-15

申请号：US16071340

申请日：2018-03-29

Applicant: Catholic University Industry Academic Cooperation Foundation

Inventor： Hyang Shuk RHIM ,  Seong Man KANG ,  Ja Young JANG

IPC: C12N9/02 ,  A61P25/28 ,  C12N15/52 ,  A61K38/44

CPC classification number: C12N9/0089 ,  C12Y115/01001 ,  A61P25/28 ,  C12N15/52 ,  A61K38/446

Abstract: The present invention relates to a biocompatible peptide inhibiting the aggregation of a β-amyloid protein, and more particularly, to a biocompatible peptide derived from superoxide dismutase 1 (SOD1) and specifically binding to β-amyloid, a β-amyloid aggregation inhibitor including the peptide, and a pharmaceutical composition for treating a β-amyloid aggregation-associated disease. The peptide of the present invention has a strong binding strength to β-amyloid, inhibits the formation of a β-amyloid protein aggregate, and prevents neural cell death, thereby treating a neurodegenerative disease such as Alzheimer's disease. In addition, since the peptide of the present invention does not have cytotoxicity, it has no side effect of disturbing an immune system.

公开(公告)号：US11123402B1

公开(公告)日：2021-09-21

申请号：US16621007

申请日：2018-06-04

Applicant: DAEGU CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION

Inventor： Hee Sung Park

IPC: A61K38/52 ,  A61K38/17 ,  A61P35/00

Abstract: An anticancer composition includes cervical cancer-derived autocrine motility factor (AMF) as an effective component. The cervical cancer-derived AMF has an excellent effect of inhibiting the proliferation of liver cancer, pancreatic cancer, breast cancer, lung cancer, prostate cancer, and colon cancer, and inducing cell death. The composition can be used as an anticancer therapeutic agent.

公开(公告)号：US20210275631A1

公开(公告)日：2021-09-09

申请号：US16621007

申请日：2018-06-04

Applicant: DAEGU CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION

Inventor： Hee Sung PARK

IPC: A61K38/17 ,  A61P35/00

Abstract: An anticancer composition includes cervical cancer-derived autocrine motility factor (AMF) as an effective component. The cervical cancer-derived AMF has an excellent effect of inhibiting the proliferation of liver cancer, pancreatic cancer, breast cancer, lung cancer, prostate cancer, and colon cancer, and inducing cell death. The composition can be used as an anticancer therapeutic agent.

公开(公告)号：US10894945B2

公开(公告)日：2021-01-19

申请号：US15463737

申请日：2017-03-20

Applicant: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION

Inventor： So-Hyang Chung ,  Hyun Jung Lee

IPC: C12N5/079

Abstract: Provided are methods for improving the proliferation and stemness of limbal stem cells (LSCs) by adding a Wnt inhibitor to a medium for limbal explant cultures. When human limbal explants are cultured according to the methods, Wnt/β-catenin signaling is inhibited, resulting in improvement of LSC proliferation, and improvement in the stemness of LSCs, and thus the LSCs may be obtained in high yield.